Company-needs-to-be-more-transparent-on-FDA-topics
The lack of transparency from company leads to more credibility in the SEC actions.
The information released from the company pertaining to FDA status is indicative of releasing just enough information to stimulate speculation, the lack of actionable progress suggests something wrong in either methods, process, strategy or likely all.
Basically company offended the integrity of the FDA authority and now is at the end of every possible queue that might exist.
It's not the FDA's fault that company leadership violated process and as result is now scrutinized to ensure the integrity of the process is not undermined.
Mess up at the DMV and go to the end of the longest line.
News 
Market Data 
Discover 
